Global Urokinase Solution Market Strategic Research Report

Scope of the Report

The global Urokinase Solution market size is predicted to grow from US$ 7.23 million in 2025 to US$ 10.40 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Urokinase Solution is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body’s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the “mesh” that holds a blood clot together. This is why urokinase is called a thrombolytic or “clot-buster.” The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.

In 2025, global Urokinase Solution production reached approximately 254.8 BIU, with an average global market price of around US$ 29 per MIU. The global single-line production capacity ranges from 10 to 15 BIU per year. The industry's gross profit margin is approximately 25%-35%.

Global key Urokinase Solution players cover Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Urokinase Solution market?

What factors are driving Urokinase Solution market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Urokinase Solution market opportunities vary by end market size?

How does Urokinase Solution break out by Type, by Application?

This report presents a comprehensive overview of the global Urokinase Solution market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Source of Human Urine
• Reorganization of Technical Production

Segment by Clinical Use

• Pulmonary Embolism Thrombolysis
• Deep Vein Thrombosis
• Peripheral Arterial Occlusion Thrombolysis
• Catheter / Cannula Occlusion Clearance
• Others

Segment by Administration Approach

• Systemic Infusion
• Catheter-directed Thrombolysis (CDT)
• Intracatheter Dwell / Lock Technique

Segment by Purity

• Standard Clinical Grade
• High-purity / Low-impurity Grade
• Low Endotoxin / Low Bioburden Specifications

Segment by Application

• Hospital
• Clinic
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Urokinase Solution market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact